Amerikanische Gesellschaft für Hirudotherapie

Finding the right fit: effective thrombosis risk stratification in orthopedic patients

Research article published in Orthopedics (2000)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewArzneimittelentwicklungArcelus JI et al. · Orthopedics, 2000

Abstract

Patients undergoing orthopedic surgery are at increased risk of venous thromboembolic events. Proven prophylactic measures are available but are generally underused. However, even one of the most effective therapies available, low-molecular-weight heparin, fails to prevent deep vein thrombosis in approximately 15% of patients undergoing total hip replacement. Clinical outcomes and cost-effectiveness of venous thromboembolism prophylaxis may be optimized by tailoring the treatment to the level of risk of each patient. Overall thromboembolic risk depends on the interactions among multiple factors, such as those that relate to the current clinical status and underlying susceptibility of the patient. Presently, risk assessment models that consider these factors may be of practical assistance in stratifying patients. Improving identification of patients with additional risk factors is a goal of future models. Novel therapies, such as the recombinant hirudin desirudin, or strategies, such as prolonged postoperative prophylaxis, may provide improved protection in these patients and should be considered in the future.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsHeparin, Low-Molecular-WeightHumansOrthopedic ProceduresPostoperative ComplicationsPredictive Value of TestsRisk AssessmentRisk FactorsVenous Thrombosis

Zusammenfassung

Finding the right fit: effective thrombosis risk stratification in orthopedic patients.

Warum dies für die Hirudotherapie relevant ist

This article examines risk stratification strategies for venous thromboembolism prophylaxis in orthopedic surgery patients, noting that even low-molecular-weight heparin fails to prevent deep vein thrombosis in approximately 15% of total hip replacements. The author identifies the recombinant hirudin desirudin as a novel therapy that may provide improved protection in high-risk patients and should be considered in the future. The abstract does not mention leeches, leech therapy, or any leech secretome, so the connection to applied hirudotherapy is not established beyond the mention of a recombinant hirudin drug. The discussion of desirudin is brief and framed as a future strategy rather than an evaluated intervention.

Zitation

Finding the right fit: effective thrombosis risk stratification in orthopedic patients

Arcelus JI et al. · Orthopedics, 2000

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.